Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Up | Up |
Historical GLSI trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% | |
Wide Range Bar | Range Expansion | 0.00% | |
Parabolic Rise | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | 6.14% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Trending on StockTwits | about 19 hours ago |
Fell Below Upper Bollinger Band | 1 day ago |
Gap Up Partially Closed | 1 day ago |
60 Minute Opening Range Breakdown | 1 day ago |
3x Volume Pace | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatments Breast Cancer Treatment Of Breast Cancer Clinical Trial Greenwich Her2 Cancer Center Her2/Neu
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 158.07 |
52 Week Low | 3.262 |
Average Volume | 722,610 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 34.87 |
20-Day Moving Average | 35.55 |
10-Day Moving Average | 41.30 |
Average True Range | 6.30 |
ADX | 46.55 |
+DI | 54.49 |
-DI | 8.83 |
Chandelier Exit (Long, 3 ATRs ) | 50.85 |
Chandelier Exit (Short, 3 ATRs ) | 46.11 |
Upper Bollinger Band | 52.47 |
Lower Bollinger Band | 18.64 |
Percent B (%b) | 1.03 |
BandWidth | 95.17 |
MACD Line | 4.77 |
MACD Signal Line | 2.14 |
MACD Histogram | 2.6263 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 82.34 | ||||
Resistance 3 (R3) | 84.53 | 77.15 | 77.55 | ||
Resistance 2 (R2) | 77.15 | 69.83 | 76.05 | 75.95 | |
Resistance 1 (R1) | 65.37 | 65.31 | 61.68 | 63.18 | 74.36 |
Pivot Point | 57.99 | 57.99 | 56.14 | 56.89 | 57.99 |
Support 1 (S1) | 46.21 | 50.67 | 42.52 | 44.02 | 32.84 |
Support 2 (S2) | 38.83 | 46.15 | 37.73 | 31.25 | |
Support 3 (S3) | 27.05 | 38.83 | 29.65 | ||
Support 4 (S4) | 24.86 |